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Summary
 
T cell costimulation, particularly by the B7 family members B7-1 and B7-2, plays a critical role
in regulating T cell–mediated immunity. Two molecules on T cells, CD28 and CTLA-4, are
known to bind to B7. It has been suggested that CD28–B7 interaction promotes T cell re-
sponse, whereas B7–CTLA-4 interaction downregulates T cell clonal expansion. However, the
proposed responses of individual receptors to B7 have not been verified directly. Here, we re-
port that B7-1 promotes clonal expansion of CD28-deficient T cells, and that the CD28-inde-
pendent costimulatory activity is mediated by CTLA-4, as it is completely blocked by intact
and Fab of anti–CTLA-4 mAb. In addition, a mutant B7-1 molecule, B7W88 
 
.
 
A, which has
lost binding to CD28 but retained significant CTLA-4 binding activity, promotes T cell clonal
expansion. Furthermore, while presence of CD28 enhances T cell response to B7-1, such re-
sponse is also completely blocked by anti–CTLA-4 mAb. Taken together, our results demon-
strate that B7–CTLA-4 interaction promotes T cell clonal expansion, and that optimal T cell
response to B7 is achieved when both CD28 and CTLA-4 interact with B7. These results es-
tablish an important function of CTLA-4 in promoting T cell activation, and suggest an alter-
native interpretation of the function of CTLA-4 in T cell activation.
 
C
 
ell surface costimulatory molecules, of which B7 fam-
ily members are known as prototypes, play an impor-
tant role in T cell responses (1–4). Two T cell surface mol-
ecules, CD28 and CTLA-4, bind B7 with different affinity
(5–8). Most T cells can express both receptors, although their
expression appears to be differentially regulated (9–11). In
addition, both receptors may initiate signal transduction, as
they are associated with an overlapping but perhaps distinct
set of molecules involved in regulating cell growth (12–17).
However, the function of the individual receptors is still
unclear.
It has been proposed that B7–CD28 interaction delivers
a positive signal, whereas B7–CTLA-4 interaction delivers
a negative signal for T cell responses (9, 10). This hypothesis
is based on two lines of evidence. First, targeted mutation
of CTLA-4 causes lethal lymphoproliferative disease (18,
19). Second, depending on experimental models, anti–
CTLA-4 mAbs either enhance or inhibit T cell clonal ex-
pansion (9, 10, 20, 21) in vitro; and in vivo, both intact and
Fab fragments of anti–CTLA-4 mAbs enhance T cell re-
sponse and tumor rejection (22–24). However, the pro-
posed inhibitory function of B7–CTLA-4 interaction has
not been directly demonstrated.
If B7–CTLA-4 interaction delivers a negative signal for
T cell growth, T cell response in CD28-deficient mice
should be enhanced when the function of B7 is blocked.
However, a study by Green et al. (25) using CD28-defi-
cient T cells has not revealed an enhancement by CTLA-4Ig.
In this study, we reevaluated the effect of B7–CTLA-4 in-
teraction on T cell clonal expansion. Our results demon-
strate that this interaction is sufficient to costimulate clonal
expansion of T cells, and that optimal T cell response to
B7-1 requires cooperation of CD28 and CTLA-4.
 
Materials and Methods
 
Experimental Animals, mAbs, and Fusion Proteins.
 
C57BL/6 mice
were purchased from the National Cancer Institute (Rockville,
MD). CD28-deficient mice (26), backcrossed to C57BL6j for six
generations, were provided by Dr. T.W. Mak (University of
Toronto, Canada).
Anti–CTLA-4 mAb 4F10 (9) and anti-CD3 mAb 2C11 (27)
were provided by Dr. J.A. Bluestone (University of Chicago,
Chicago, IL). Anti–B7-1 mAb 16.10A1 (28) was provided by Dr.
H. Reiser (Dana-Farber Cancer Institute, Boston, MA). Another
anti–B7-1 mAb 3A12 was produced in this laboratory and has
been described (29). Anti-CD45RB mAb C363.16A (30) was
provided by Dr. K. Bottomly (Yale University, New Haven,
CT), anti-CD11c mAb HB224 (31) was a gift from Dr. R. Stein-
man (Rockefeller University, New York). Intact mAbs were pu-
rified by a protein G column, while the Fab fragments were pre-
pared using a Fab kit (catalog no. 44885) from Pierce Chemical
Company (Rockford, IL) according to the manufacturer’s in-
structions. The purity of both intact and Fab fragments was veri-
fied by 10% SDS-PAGE.
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Construction and production of fusion proteins, murine
CTLA-4Ig, and CD28Ig have been fully described (32).
 
Transfection of COS and Chinese Hamster Ovary Cells.
 
COS cells
were transfected with wild-type and mutant B7-1 molecules by
DEAE–dextran methods, as has been described (33). The proce-
dure for Chinese hamster ovary (CHO)
 
1
 
 cell transfection has also
been described (34).
 
Flow Cytometry.
 
Expression of wild-type and mutant B7-1
was determined by flow cytometry using anti–B7-1 mAbs, either
16.10A1, or 3A12, as primary antibody, and FITC-labeled goat
anti–hamster IgG was used as second-step reagent, as has been de-
scribed. Fusion proteins, either CD28Ig or CTLA-4Ig, were used
as first-step reagents. The binding to wild-type and mutant B7-1
was determined by using FITC-labeled goat anti–mouse IgG as
second-step reagents.
 
Proliferation Assay.
 
CD4 T cells were purified from spleen
cells as described (35). The purity of CD4 T cells isolated was
 
.
 
95%. Given numbers of the CD4 T cells were stimulated with
anti-CD3 mAb (0.25 
 
m
 
g/ml) using mitomycin C (100 
 
m
 
g/ml, 37
 
8
 
C
for 1 h)–treated CHO cells transfected with either FcR (CHOFcR)
or FcR plus murine B7-1 (CHOFcRB7). The cultures were
maintained for 42 h, and were pulsed with [
 
3
 
H]TdR (1.25 
 
m
 
Ci/
well) for an additional 6 h. The cultures were then harvested and
the [
 
3
 
H]TdR incorporated into the genomes was determined by a
betaplate counter. The blocking mAbs were added at the begin-
ning of the culture. The data presented are means of duplicates
with variation 
 
,
 
15% of the mean.
In some experiments, CD4 T cells were separated based on
their cell surface expression of CD45RB. In brief, CD4 T cells
were incubated with anti-CD45RB mAb C363.16A (5 
 
m
 
g/ml)
for 1 h at 4
 
8
 
C; the unbound antibodies were washed away. After
adding DYNAL beads coated with goat anti–rat Ig for 1 h, the
cells that bound to C363.16A were collected by magnet. The
cells bound to the beads were eluted by adding 2 mg/ml of nor-
mal rat Ig at 37
 
8
 
C for 1 h and used as naive cells. The cells that
did not bind DYNAL beads in the first place were depleted once
more with DYNAL beads and used as memory cells. The
CD45RB profiles were determined by flow cytometry using ei-
ther C363.16A (CD45RB) or medium (control) as the first-step
reagent and FITC-labeled mouse anti–rat Ig as second-step re-
agent.
 
Site-directed Mutagenesis.
 
Site-directed mutagenesis of murine
B7-1 was achieved by PCR using oligonucleotides carrying the
desired mutations. B7Y that carries a mutation from Y 
 
.
 
A at po-
sition 201 has been described (32). Mutant B7W (W 
 
.
 
A at posi-
tion 88) was created as follows. A B7-1 fragment containing the
desired mutation was produced by PCR using GCTCGA-
GAAGCTTATGGCTTGCAATTGTCAG as forward primer,
and CTTAGCCTCGGGCGCCAC TTTTAGTTTCCC as re-
verse primer. After digestion by AvaI, the PCR product was li-
gated to the AvaI–XbaI fragment of murine B7-1 (32). B7L (L109
 
.
 
A) was created by a two-step PCR. First, a mutant B7-1 frag-
ment containing the desired mutation (L 
 
.
 
A) is generated using
GCTCGAGAAGCTTATGGCTTGCAATTGTCAG as forward
primer, and CGACGCAGCTGTAGGTGCCCCGGTCGCT-
AGCGACCAGGC as reverse primer; another fragment covering
the remaining sequence of B7-1 open reading frame is amplified
using CACCTACAGCTGCGTCGTTCAAAAGAAGGA as for-
ward primer and CGAATTCTAGAACTAAAGGAAGACGG-
TCT as reverse primer. Second, a mixture of the two B7-1 frag-
ments were used as template to amplify the full-length B7-1 mutant;
GGCTCTAGATTCCTGGCTTTCCCCATCATG was used as
forward primer and GTCAGCCATCTCGAGTTTTTCCCA-
GGTGAAGTC was used as reverse primer. The PCR condition
has been described (32).
 
Results
 
CD28-independent Costimulatory Activity of B7-1.
 
To ex-
amine the function of CD28 and CTLA-4, we compared
wild-type and CD28-deficient T cells in their response to
costimulation by B7 in vitro. We produced CHO cells
transfected with either FcR (CHOFcR), which cross-links
anti-CD3 mAb on T cell surface, or FcR in conjunction
with murine B7-1 (CHOFcRB7) (23), and tested their co-
stimulatory activity for clonal expansion of CD4 T cells
from wild-type and CD28(
 
2
 
/
 
2
 
) mice. As expected, wild-
type CD4 T cells respond to costimulation by B7-1 (Fig. 1 
 
a
 
).
Surprisingly, T cells from CD28-deficient mice also mount
a positive response to B7-1, although the response is ap-
proximately fivefold lower than that of wild-type T cells
(Fig. 1 
 
b
 
). The critical role of B7-1 is confirmed, as an anti–
B7-1 mAb 3A12 (29) significantly blocks responses of wild-
type and CD28-deficient T cells. In addition, CD4 T cells
from wild-type and CD28-deficient mice bearing naive or
memory markers both respond positively to costimulation
by B7-1 (Fig. 2). These results demonstrate that B7-1 can
costimulate T cell clonal expansion by a CD28-indepen-
dent mechanism.
Figure 1. Costimulatory molecule B7-1 significantly enhances anti-
CD3–induced proliferative responses of CD4 T cells from either wild-
type (a) or CD28-deficient (b) mice. Varying numbers of the wild-type (a)
and CD28-deficient (b) CD4 T cells were stimulated with anti-CD3 mAb
and mitomycin C–treated CHO cells that were transfected with either
FcR (CHOFcR) or FcR plus murine B7-1 (CHOFcRB7) (104/well).
The cultures were maintained for 42 h, and were pulsed with [3H]TdR
(1.25 mCi/well) for an additional 6 h. Either normal hamster Ig or anti-B7
mAb 3A12 was added at the beginning of the culture to evaluate the con-
tribution of B7-1 to T cell proliferation. cpm of [3H]TdR incorporated
into mitomycin-treated CHO cells: CHOFcR, 326; CHOFcRB7, 1474.
The CD28-independent costimulatory activity of B7-1 has been repeated
10 times.
 
1
 
Abbreviation used in this paper:
 
 CHO, Chinese hamster ovary. 
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Contribution of CTLA-4 to B7-1–mediated Costimulation.
 
To verify the contribution of CTLA-4, we tested whether
an anti–CTLA-4 mAb affects the function of B7-1. We pre-
pared Fab of the mAb by papain digestion and depletion of
Fc-containing immunoglobulin. As shown in Fig. 3, in
SDS-PAGE under reducing conditions, intact mAb prepa-
ration consists of two peptides of 
 
z
 
50 kD and 
 
z
 
28 kD, the
respective molecular masses of the heavy and light chain of
IgG. Fab preparation run as one band of 
 
z
 
28 kD, which
indicate that the Fab used for the study is free of detectable
intact Ig. As shown in Fig. 4, the anti–CTLA-4 mAb 4F10
completely blocks the function of B7-1. This blocking
does not require cross-linking of CTLA-4, as the Fab frag-
ment of the mAb also blocked the function of T cells. Sur-
prisingly, both intact and Fab fragment of anti–CTLA-4
mAb inhibit response of CD28(
 
1
 
/
 
1
 
) T cells. The ability
of both intact and Fab of anti–CTLA-4 mAb 4F10 to block
the function of wild-type T cells indicates that CTLA-4 is
critically involved in B7-1–mediated costimulation for wild-
type T cells.
A potential caveat of this interpretation is that anti–
CTLA-4 may negatively signal T cells and thus prevent
T cell clonal expansion regardless of the presence of B7-1.
To rule out this possibility, we tested whether anti–CTLA-4
mAb inhibits T cell response to costimulation by CD44H,
which we recently identified as a CD40L-induced costim-
ulatory molecule that promotes T cell clonal expansion by
a CD28-independent mechansim (36). As shown in Fig. 5,
anti–CTLA-4 mAb 4F10 does not inhibit clonal expansion
of T cells when CHO cells expressing murine CD44H are
used as costimulator. These results confirm that anti–
CTLA-4 mAb is a specific inhibitor of T cell response to
costimulation by B7-1.
 
Functional Analysis of B7-1 Mutant Supports CTLA-4 as a
Positive Regulator for T Cell Clonal Expansion.
 
Anti–CTLA-4
mAbs show different effects on T cell proliferation depend-
ing whether costimulation is provided by anti-CD28 or by
antigen-presenting cells (9, 10, 20–24). To avoid any ques-
tion that may be associated with antibody blocking studies,
we have carried out a systematic site-directed mutagenesis
of B7-1 molecules in both IgC-like (32) and IgV-like do-
mains in search of a mutant B7 that retains binding for
CTLA-4 but not CD28. As shown in Fig. 6 
 
a
 
, saturating
amount of CTLA-4Ig binds B7W, which carries a muta-
tion from W to A at position 88 of B7-1 (number starts at
the first methionine encoded by B7-1 cDNA), at levels
comparable to those of wild-type B7, although careful ti-
tration of CTLA-4Ig reveals that it takes about ninefold more
Figure 2. CD4 T cells expressing either naive or memory markers are
capable of responding to B7-1 by a CD28-independent mechanism. (a)
CD45RB profiles of the subsets of CD4 T cells used in the study. (b) Pro-
liferative responses of CD4 T subsets from either wild-type (WT) or
CD28(2/2) mice to soluble anti-CD3 using CHO cells transfected with
either FcR or FcR plus murine B7-1 as accessory cells.
Figure 3. Fab preparation
used in the study does not con-
tain intact mAb. Anti–CTLA-4
mAb 4F10 was purified by affin-
ity purification. Purified mAb
was digested with papain, and
Fc-containing molecules re-
moved using immobilized pro-
tein A. 5 mg of intact and 2 mg
of Fab were analyzed by 105
SDS-PAGE under reducing con-
ditions.
Figure 4. Both intact and Fab fragments of anti–CTLA-4 mAb block
the costimulatory activity of B7-1. Purified CD4 T cells (105/well) either
wild-type (a) and CD28-deficient (b) mice were stimulated with soluble
anti-CD3 mAb (0.25 mg/ml) in the presence of mitomycin C–treated
CHO cells (3 3 103/well) transfected with FcR plus B7-1 (FcRB7) for
48 h. The proliferation of CD4 T cells was determined by incorporation
of [3H]TdR in the last 6 h of culture. Given concentrations of intact or
Fab fragment of anti–CTLA-4 mAb 4F10, or control mAb HB224 were
added at the beginning of the culture. Data shown represent five indepen-
dent experiments. 
1330
 
Positive Regulation of T Cell Activation by CTLA-4
 
CTLA-4Ig to achieve such saturation for B7W (Fig. 6 
 
c
 
). In
contrast, B7W does not bind CD28Ig (Fig. 6 
 
b
 
). Mutant
B7 L109 
 
.
 
A (B7L), which binds CTLA-4Ig less well than
B7W, binds CD28 even better than wild-type B7-1. On
the other hand, mutant B7Y, which has a mutation at posi-
tion 201 from Y to A, does not show detectable binding to
either CD28Ig or CTLA-4Ig, as we have reported (32).
These results demonstrate that B7-1 is recognized by the
two receptors asymmetrically, and the selective loss of CD28
binding activity in B7W cannot be accounted for simply on
the basis of low avidity of CD28–B7 interaction. The pref-
erential effect of B7W 
 
.
 
A mutation on CD28 binding is
consistent with an earlier mutagenesis analysis involving
human B7-1 expressed on fibroblasts (37), although it is ap-
parently at variance with mutagenesis analysis using recom-
binant human B7-1 fusion protein (38), perhaps owing to
differential glycosylation of B7-1.
Therefore, we transfected B7-1, B7W, and B7Y into
CHOFcR cells, and produced stable cell lines expressing
comparable levels of FcR and wild-type or mutant B7-1
(Fig. 7 
 
a
 
). These cell lines were used to determine the re-
ceptors responsible for the costimulatory activity of B7-1.
As shown in Fig. 7 
 
b
 
, both wild-type and CD28-deficient
T cells respond to costimulation by wild-type B7-1 and
B7W, but not to that by B7Y. Thus, CTLA-4 binding ac-
tivity is sufficient to costimulate T cell proliferation. More-
over, wild-type T cells respond to B7-1 significantly better
than to B7W, as 
 
z
 
20-fold more CHO cells expressing B7W
Figure 5. Specificity of inhibition by anti–CTLA-4 mAb. Wild-type (a–c, 5 3 104/well) or CD28(2/2) (d–f, 105/well) CD4 T cells were stimulated
with anti-CD3 mAb and CHO cells (mitomycin C–treated, 3,000/well) transfected with either FcR, FcR plus B7-1 (FcRB7), or FcR plus CD44H
(FcRCD44H) for 48 h in the presence of control mAb HB224, anti–B7-1 mAb 10.16A, and anti–CTLA-4 mAb 4F10. (a and d) Proliferation of wild-
type and CD28(2/2) T cells to anti-CD3 in the presence of CHOFcR, CHOFcRB7, and CHOFcR CD44H. Note that twice as many CD28(2/2)
CD4 T cells were used to ensure a comparable total proliferative response. (b and e) Lack of inhibition by anti–CTLA-4 mAb when CD44H was used as
costimulator. (c and f) Inhibition by anti–B7-1 and anti–CTLA-4 when B7-1 was used as costimulators. 
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are required to achieve a level of T cell proliferation similar
to that costimulated by wild-type B7-1. This difference is
diminished when CD28(
 
2
 
/
 
2
 
) CD4 T cells are used, thus
confirming the inability of B7W to stimulate CD28. The
function of B7W is blocked by anti–B7-1 and anti–CTLA-4
mAbs (Fig. 8).
 
Discussion
 
CTLA-4 plays an important role in regulating T cell
function, as evidence by the phenotypes of CTLA-4–defi-
cient mice (17, 18) and by the effect of anti–CTLA-4
mAbs (9–11). The biological consequences of B7–CTLA-4
interactions have not been studied in detail. Here we seek
to measure directly the effect of B7–CTLA-4 interaction
on T cell clonal expansion. Our results demonstrate that
B7–CTLA-4 interaction is sufficient to induce T cell clonal
expansion in vitro.
First, T cells from CD28-deficient mice react to costimu-
lation by B7-1, although the proliferative response is gener-
ally 5 to 10-fold lower than wild-type T cells. This response
is mediated by CTLA-4 on T cells, because anti-CTLA-4
mAb, either intact or Fab, blocks B7-1–dependent T cell
proliferation. Surprisingly, in numerous experiments, anti–
CTLA-4 mAb also completely inhibit B7-1–mediated pro-
liferation of wild-type T cells. Because this mAb does not
interfere with T cell proliferation when CD44H is used as
costimulator (Fig. 5), it is unlikely that this mAb inhibits T
cell response to B7-1 by negative signaling. These results
suggest that B7–CD28 interaction may not be sufficient to
promote T cell proliferation. This is paradoxical, given the
fact that anti-CD28 mAb used as the prototypic costimula-
tor for T cell clonal expansion (39–43), although it has not
been demonstrated whether B7–CD28 interaction is suffi-
cient to costimulate T cell proliferation. Because anti-CD28
mAb 9.3 has 
 
z
 
100-fold higher avidity than B7-1Ig for
CD28 (7), this paradox can be reconciled by higher avidity
of the anti-CD28 mAb. It should be noted that in an earlier
report, Green et al. (25) failed to detect CD28-indepen-
dent function of B7-1 in promoting T cell clonal expansion
in the presence of PMA. This difference can be explained
by possible lack of expression of CTLA-4 in the CD28(
 
2
 
/
 
2
 
)
cells used by Green et al. Alternatively, our assay based on
copresentation of TCR ligand and costimulator B7-1 on
the same cells (44) is 
 
z
 
20-fold more sensitive than the ear-
lier study; the difference can be reconciled on the basis of
sensitivity of the assays.
Second, mutant B7-1, B7W, which lacks detectable CD28
binding activity, promotes proliferation of both wild-type
and CD28-deficient T cells. For better quantitation, we
measured CD28 binding using fusion protein CD28Ig. How-
ever, our preliminary data indicated that CD28 expressed
Figure 6. Characterization of B7-1 mutants. (a) FACSÒ profiles for the binding of wild-type and mutant B7 molecules, expressed on COS cells by
transient transfection, to saturating amount of CD28Ig (100 mg/ml) and CTLA-4Ig (10 mg/ml) and anti-B7-1 mAb 10.16A (10 mg/ml). Numbers in each
panel are mean fluorescences. (b and c) Quantitative analysis of CD28Ig and CTLA-4Ig binding to wild-type and mutant B7-1 (16, 23). COS cells were
either mock-transfected or transfected with wild-type and mutant B7 cDNA. The COS cells were used to determine ability of wild-type and mutant B7
to bind varying concentration of either CD28Ig or CTLA-4Ig. The data shown are mean fluorescences normalized for the cell surface expression of B7-1
according to the following formula: Normalized MF for receptor binding 5 (MFmutant 2 MFmock) 3 k, where k 5 (MFmutant 2 MFmock) / (MFWT 2 MFmock)
when anti-B7-1 mAb 10.16A is used to measure cell surface expression of wild-type or mutant B7-1. Representative of three independent experiments.1332 Positive Regulation of T Cell Activation by CTLA-4
on CHO cells as a transmembrane protein also fail to medi-
ate adhesion to B7W (data not shown), much like human
B7-1 with a mutation of the corresponding amino acid (37).
Furthermore, while mutant B7W stimulates wild-type T cells
less well than wild-type B7-1, it is comparable to wild-type
B7-1 if CD28(2/2) T cells are used as responder. Thus,
the major functional difference between B7W and wild-
type B7-1 is in their interaction with CD28. Our func-
tional analysis of B7-1 mutant indicates that B7–CTLA-4
binding is sufficient to costimulate wild-type and CD28-
deficient T cells. The use of B7-1 mutants allows us to dis-
sect the function of CTLA-4 without the caveats of anti–
CTLA-4 mAb.
A recent study suggests that another yet unidentified re-
ceptor for B7 may exist on NK cells (45). An intriguing
question is whether the CD28-independent response to
Figure 7. CTLA-4 binding activity is required for CD28-independent costimulation by B7-1. (a) Levels of FcR and B7 on CHO cells transfected with
wild-type and mutant B7-1 measured by antiFcR mAb 2.4G2 or anti–B7-1 mAb 3A12. (b and c) Costimulatory activity of wild-type and B7 mutant
B7W (88W .A) and B7Y (201Y .A) for either wild-type (b) or CD28(2/2) (c) T cells. Wild-type and CD28-deficient CD4 T cells were stimulated
with anti-CD3 mAb and 104/well of mitomycin C–treated CHO cells. Data presented are representatives of three independent experiments.
Figure 8. Anti–CTLA-4 mAb inhibits B7W-mediated costimulation
for clonal expansion of T cells from wild-type and CD28-deficient mice.
CD4 T cells (105/well) were stimulated for 48 h by anti-CD3 mAb and
mitomycin C–treated CHO cells that have been transfected with both
FcR and B7W (104/well). Given concentration of anti–CTLA-4 mAb
4F10, anti–B7-1 mAb 3A12, and control anti-CD11c mAb HB224 was
added at the beginning of culture. Data presented are representatives of
three independent experiments.1333 Wu et al.
B7-1, as reported here, is mediated by a yet unidentified
receptor for B7-1. Although it is impossible to rule out a
possible contribution of other unknown receptors, CTLA-4
is at least an essential part of the signaling complex, because
the CD28-independent function of B7-1 is completely
blocked by anti–CTLA-4 mAb.
Taken together, our results presented in this report dem-
onstrate that B7–CTLA-4 interaction promotes T cell
clonal expansion. Moreover, optimal costimulation by B7
requires both CD28 and CTLA-4, as has been proposed by
Linsley et al. (11). The mechanism of the cooperation be-
tween CD28 and CTLA-4 is still unclear at the present.
B7–CD28 interaction may be critical for enhancing IL-2
production. Thus, it has been reported that CD28 defi-
ciency leads to a drastic reduction in IL-2 production (25,
26, 37). Our analysis of IL-2 production in CD28-deficient
T cells (data not shown) also supports this concept. In addi-
tion, mutant B7W, which bind CTLA-4 but not CD28,
promotes T cell clonal expansion but barely enhances IL-2
production (data not shown). Therefore, unlike CD28-B7
interaction, CTLA-4–B7 interaction may not enhance T
cell response by increasing the production of IL-2. Our re-
sults are inconsistent with the notion that CTLA-4 is a
negative regulator for T cell activation, although it is con-
ceivable that CTLA-4 may downregulate T cell activation
on other circumstances. Several important factors, such as
expression and cellular localization of CTLA-4 may influ-
ence the function of CTLA-4. Although it is clear that the
expression and cellular expression of CTLA-4 is under
stringent control (47), the regulatory mechanisms are not
well understood. This lack of knowledge has made it diffi-
cult to predict the function of CTLA-4 under physiological
conditions.
Several recent studies have shown that anti–CTLA-4
mAbs can be potent enhancers of immune response to de-
fined foreign antigen, self-antigens, and tumors (22–24).
Although these results were interpreted in the light of
blocking negative signal from CTLA-4, it is also possible
that these results are achieved by enhancing positive signal
transduction from CTLA-4. The mutant B7-1 molecules
described in this study may help to resolve the function of
CTLA-4 in vivo. The answer to this question will be criti-
cal for immune intervention targeted at CTLA-4, as it will
determine whether signal transduction initiated by CTLA-4
should be amplified or inhibited.
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